Previous 10 | Next 10 |
2023-04-10 22:25:44 ET The U.S. government is launching a $5B-plus program to accelerate the development of new coronavirus vaccines and treatments, officials from the Biden administration and the Department of Health and Human Services ( HHS ) confirmed Monday. An HHS official said...
2023-04-10 00:38:00 ET Summary Duality Biologics (Suzhou) out-licensed global rights (ex-China) for two ADC candidates to BioNTech in a deal worth $170 million upfront and up to $1.5 billion in milestone payments. Shanghai HutchMed has completed the rolling submission of a US NDA ...
2023-04-06 14:14:11 ET After more than three years, the World Health Organization (WHO) could announce an end to the emergency status of COVID-19 this year, the head of the global body Dr. Tedros Adhanom Ghebreyesus, said Thursday. In early 2020, the WHO named the COVID-19 pandemic a Pu...
2023-04-04 08:15:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Companies seek compensation for Pfizer’s and BioNTech’s unlicensed use of patented technologies in COVID-19 mRNA-LNP vaccines WARMINSTER, Pa., April 04, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus”), a clinical-stage biop...
2023-04-03 18:44:09 ET In the next few weeks, the US FDA is likely to authorize a second booster shot specifically targeting COVID-19 Omicron variants for older individuals and those with weakened immune systems. The Washington Post reported that the goal is to provide those who...
2023-04-03 07:21:41 ET BioNTech ( NASDAQ: BNTX ) signed a licensning agreement with Duality Biologics (Suzhou) (DualityBio) for two antibody-drug conjugate (ADC) assets for solid tumors. Under the agreements, DualityBio will get $170M upfront for both asset licens...
BioNTech receives exclusive licenses from DualityBio for two investigational antibody-drug conjugate assets (DB-1303 and DB-1311) directed against targets expressed in a broad range of human cancers Collaboration will add a new class of precision medicine therapeutics to BioNTech’s...
2023-03-30 09:00:30 ET Moderna ( NASDAQ: MRNA ) signed an agreement with the government of the Republic of Kenya to set up an mRNA manufacturing facility in the African nation. This will be Moderna's first mRNA manufacturing facility in Africa. The facility, which w...
2023-03-28 13:41:06 ET Vaccine-developer Gritstone bio ( NASDAQ: GRTS ) trended higher on Tuesday after B. Riley launched its coverage with a Buy rating and a 12-month target of $8 per share, noting its prospects in messenger RNA technology. The analyst Mayank Mamtani argues...
News, Short Squeeze, Breakout and More Instantly...
BioNTech SE Company Name:
BNTX Stock Symbol:
NYSE Market:
Initial data from the ongoing Phase 2 trial showed a 12-month overall survival (OS) rate of 69% and median overall survival (mOS) of 17.5 months in patients with previously treated PD-L1-positive mNSCLC treated with combination of acasunlimab with pembrolizumab every six weeks Data from t...
BioNTech and CEPI aim to enhance local R&D, clinical and commercial-scale manufacturing capacities to develop potential mRNA vaccines in Africa, for Africa CEPI to fund up to $145 million to support BioNTech in broadening the scope of the manufacturing facility in Kigali, Rwanda, aime...
On CNBC's “Mad Money Lightning Round,” Jim Cramer called Celestica Inc. (NYSE:CLS) “terrific” after the Toronto-based ...